Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
European Radiology
Erschienen in:

20.01.2022 | Imaging Informatics and Artificial Intelligence

The application of radiomics in predicting gene mutations in cancer

verfasst von: Yana Qi, Tingting Zhao, Mingyong Han

Erschienen in: European Radiology | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

With the development of genome sequencing, the role of molecular targeted therapy in cancer is becoming increasingly important. However, genetic testing remains expensive, invasive, and time-consuming, and thus unavailable for all patients. Radiogenomics aims to correlate imaging characteristics with gene expression patterns, gene mutations, and other genome-related characteristics. Due to the noninvasive nature of medical imaging, the field of radiogenomics is rapidly developing and may serve as a substitute tool for genetic testing. In this article, we briefly summarise the current role of radiogenomics in predicting gene mutations in brain, lung, colorectal, breast, and kidney tumours.

Key Points

• The role of molecular targeted therapy in individual cancer-precision therapy is becoming increasingly important with the development of genetic testing.
• Radiogenomics may provide accurate imaging biomarkers as a substitute for genetic testing.
• While the field of radiogenomics holds great promise, there are still a number of limitations that need to be overcome.
Literatur
1.
Wang R, Han L, Dai W et al (2020) Cause of death for elders with colorectal cancer: a real-world data analysis. J Gastrointest Oncol 11:269–276PubMedPubMedCentralCrossRef
2.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424PubMedCrossRef
3.
Cox VL, Bhosale P, Varadhachary GR et al (2017) Cancer genomics and important oncologic mutations: a contemporary guide for body imagers. Radiology 283:314–340PubMedCrossRef
4.
Lee SM, Lewanski CR, Counsell N et al (2014) Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases. J Natl Cancer Inst 106:dju151PubMedPubMedCentral
5.
Novello S (2015) Epidermal growth factor receptor tyrosine kinase inhibitors as adjuvant therapy in completely resected non-small-cell lung cancer. J Clin Oncol 33:3985–3986PubMedCrossRef
6.
Kelly K, Altorki NK, Eberhardt WE et al (2015) Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol 33:4007–4014PubMedCrossRef
7.
Rizzo S, Petrella F, Buscarino V et al (2015) CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer. Eur Radiol 26:32–42PubMedCrossRef
8.
Hsu JS, Huang MS, Chen CY et al (2014) Correlation between EGFR mutation status and computed tomography features in patients with advanced pulmonary adenocarcinoma. J Thorac Imaging 29:357–363PubMedCrossRef
9.
Yamamoto S, Korn RL, Oklu R et al (2014) ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. Radiology 272:568–576PubMedCrossRef
10.
Aerts HJ, Velazquez ER, Leijenaar RT et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5:4006PubMedCrossRef
11.
Lambin P, Rios-Velazquez E, Leijenaar R et al (2012) Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 48:441–446PubMedPubMedCentralCrossRef
12.
Pinker K, Shitano F, Sala E et al (2018) Background, current role, and potential applications of radiogenomics. J Magn Reson Imaging 47:604–620PubMedCrossRef
13.
Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures, they are data. Radiology 278:563–577PubMedCrossRef
14.
Kleesiek J, Kersjes B, Ueltzhoffer K et al (2021) Discovering digital tumor signatures-using latent code representations to manipulate and classify liver lesions. Cancers (Basel) 13:3108CrossRef
15.
16.
Rathore S, Akbari H, Rozycki M et al (2018) Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1. Sci Rep 8:5087PubMedPubMedCentralCrossRef
17.
Sutton EJ, Dashevsky BZ, Oh JH et al (2016) Breast cancer molecular subtype classifier that incorporates MRI features. J Magn Reson Imaging 44:122–129PubMedPubMedCentralCrossRef
18.
Moitra D, Mandal RK (2020) Prediction of non-small cell lung cancer histology by a deep ensemble of convolutional and bidirectional recurrent neural network. J Digit Imaging 33:895–902PubMedPubMedCentralCrossRef
19.
Coroller TP, Grossmann P, Hou Y et al (2015) CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. Radiother Oncol 114:345–350PubMedPubMedCentralCrossRef
20.
Vallieres M, Freeman CR, Skamene SR, El Naqa I (2015) A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities. Phys Med Biol 60:5471–5496PubMedCrossRef
21.
Ainsworth NL, McLean MA, McIntyre DJO et al (2016) Quantitative and textural analysis of magnetization transfer and diffusion images in the early detection of brain metastases. Magn Reson Med 77:1987–1995PubMedPubMedCentralCrossRef
22.
Ganeshan B, Miles KA, Babikir S et al (2017) CT-based texture analysis potentially provides prognostic information complementary to interim FDG-PET for patients with Hodgkin's and aggressive Non-Hodgkin's lymphomas. Eur Radiol 27:1012–1020PubMedCrossRef
23.
Groheux D, Martineau A, Teixeira L et al (2017) (18)FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis. Breast Cancer Res 19:3PubMedPubMedCentralCrossRef
24.
Liu S, Liu S, Ji C et al (2017) Application of CT texture analysis in predicting histopathological characteristics of gastric cancers. Eur Radiol 27:4951–4959PubMedCrossRef
25.
Lee SJ, Zea R, Kim DH, Lubner MG, Deming DA, Pickhardt PJ (2018) CT texture features of liver parenchyma for predicting development of metastatic disease and overall survival in patients with colorectal cancer. Eur Radiol 28:1520–1528PubMedCrossRef
26.
Ostrom QT, Gittleman H, Farah P et al (2013) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 15(Suppl 2):ii1-i56PubMedPubMedCentralCrossRef
27.
Delgado-Lopez PD, Corrales-Garcia EM (2016) Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol 18:1062–1071PubMedCrossRef
28.
29.
Yang D, Rao G, Martinez J, Veeraraghavan A, Rao A (2015) Evaluation of tumor-derived MRI-texture features for discrimination of molecular subtypes and prediction of 12-month survival status in glioblastoma. Med Phys 42:6725–6735PubMedPubMedCentralCrossRef
30.
Mazurowski MA, Clark K, Czarnek NM, Shamsesfandabadi P, Peters KB, Saha A (2017) Radiogenomics of lower-grade glioma: algorithmically-assessed tumor shape is associated with tumor genomic subtypes and patient outcomes in a multi-institutional study with The Cancer Genome Atlas data. J Neurooncol 133:27–35
31.
Li Z, Wang Y, Yu J, Guo Y, Cao W (2017) Deep learning based radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma. Sci Rep 7:5467PubMedPubMedCentralCrossRef
32.
Eichinger P, Alberts E, Delbridge C et al (2017) Diffusion tensor image features predict IDH genotype in newly diagnosed WHO grade II/III gliomas. Sci Rep 7:13396PubMedPubMedCentralCrossRef
33.
34.
Bisdas S, Shen H, Thust S et al (2018) Texture analysis- and support vector machine-assisted diffusional kurtosis imaging may allow in vivo gliomas grading and IDH-mutation status prediction: a preliminary study. Sci Rep 8:6108PubMedPubMedCentralCrossRef
35.
Kim M, Jung SY, Park JE et al (2020) Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma. Eur Radiol 30:2142–2151PubMedCrossRef
36.
Jakola AS, Zhang YH, Skjulsvik AJ et al (2018) Quantitative texture analysis in the prediction of IDH status in low-grade gliomas. Clin Neurol Neurosurg 164:114–120PubMedCrossRef
37.
Zhou H, Vallieres M, Bai HX et al (2017) MRI features predict survival and molecular markers in diffuse lower-grade gliomas. Neuro Oncol 19:862–870PubMedPubMedCentralCrossRef
38.
Park YW, Han K, Ahn SS et al (2018) Whole-tumor histogram and texture analyses of DTI for evaluation of IDH1-mutation and 1p/19q-codeletion status in World Health Organization grade II Gliomas. AJNR Am J Neuroradiol 39:693–698PubMedPubMedCentralCrossRef
39.
Li Y, Liu X, Xu K et al (2018) MRI features can predict EGFR expression in lower grade gliomas: a voxel-based radiomic analysis. Eur Radiol 28:356–362PubMedCrossRef
40.
Lee J, Narang S, Martinez JJ, Rao G, Rao A (2015) Associating spatial diversity features of radiologically defined tumor habitats with epidermal growth factor receptor driver status and 12-month survival in glioblastoma: methods and preliminary investigation. J Med Imaging (Bellingham) 2:041006CrossRef
41.
Li Y, Liu X, Qian Z et al (2018) Genotype prediction of ATRX mutation in lower-grade gliomas using an MRI radiomics signature. Eur Radiol 28:2960–2968PubMedCrossRef
42.
Ren Y, Zhang X, Rui W et al (2019) Noninvasive prediction of IDH1 mutation and ATRX expression loss in low-grade gliomas using multiparametric MR radiomic features. J Magn Reson Imaging 49:808–817PubMedCrossRef
43.
Li Y, Qian Z, Xu K et al (2018) MRI features predict p53 status in lower-grade gliomas via a machine-learning approach. Neuroimage Clin 17:306–311PubMedCrossRef
44.
45.
Lindeman NI, Cagle PT, Aisner DL et al (2018) Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn 20:129–159PubMedCrossRef
46.
Kalemkerian GP, Narula N, Kennedy EB et al (2018) Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol 36:911–919PubMedCrossRef
47.
Wu YL, Planchard D, Lu S et al (2019) Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol 30:171–210PubMedCrossRef
48.
Han JY, Park K, Kim SW et al (2012) First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 30:1122–1128PubMedCrossRef
49.
Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246PubMedCrossRef
50.
Solomon BJ, Mok T, Kim DW et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167–2177PubMedCrossRef
51.
Nishio M, Kim DW, Wu YL et al (2018) Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer. Cancer Res Treat 50:691–700PubMedCrossRef
52.
53.
Yucel S, Sayit AT, Tomak L, Celenk C (2021) Frequency of complications and risk factors associated with computed tomography guided core needle lung biopsies. Ann Saudi Med 41:78–85PubMedPubMedCentralCrossRef
54.
Song L, Zhu Z, Mao L et al (2020) Clinical, conventional CT and radiomic feature-based machine learning models for predicting ALK rearrangement status in lung adenocarcinoma patients. Front Oncol 10:369PubMedPubMedCentralCrossRef
55.
Tu W, Sun G, Fan L et al (2019) Radiomics signature: a potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology. Lung Cancer 132:28–35PubMedCrossRef
56.
Wang S, Shi J, Ye Z et al (2019) Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning. Eur Respir J 53:1800986PubMedPubMedCentralCrossRef
57.
Zhang J, Zhao X, Zhao Y et al (2020) Value of pre-therapy (18)F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 47:1137–1146PubMedCrossRef
58.
Jiang M, Zhang Y, Xu J et al (2019) Assessing EGFR gene mutation status in non-small cell lung cancer with imaging features from PET/CT. Nucl Med Commun 40:842–849PubMedCrossRef
59.
60.
Zhao W, Wu Y, Xu Y et al (2019) The potential of radiomics nomogram in non-invasively prediction of epidermal growth factor receptor mutation status and subtypes in lung adenocarcinoma. Front Oncol 9:1485PubMedCrossRef
61.
Yang X, Dong X, Wang J et al (2019) Computed tomography-based radiomics signature: a potential indicator of epidermal growth factor receptor mutation in pulmonary adenocarcinoma appearing as a subsolid nodule. Oncologist 24:e1156–e1164PubMedPubMedCentralCrossRef
62.
Jia TY, Xiong JF, Li XY et al (2019) Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling. Eur Radiol 29:4742–4750PubMedCrossRef
63.
Li X, Yin G, Zhang Y et al (2019) Predictive power of a radiomic signature based on (18)F-FDG PET/CT images for EGFR mutational status in NSCLC. Front Oncol 9:1062PubMedPubMedCentralCrossRef
64.
Li Y, Lu L, Xiao M et al (2018) CT slice thickness and convolution kernel affect performance of a radiomic model for predicting EGFR status in non-small cell lung cancer: a preliminary study. Sci Rep 8:17913PubMedPubMedCentralCrossRef
65.
Chang C, Sun X, Wang G et al (2021) A machine learning model based on PET/CT radiomics and clinical characteristics predicts ALK rearrangement status in lung adenocarcinoma. Front Oncol 11:603882PubMedPubMedCentralCrossRef
66.
Rios Velazquez E, Parmar C, Liu Y et al (2017) Somatic mutations drive distinct imaging phenotypes in lung cancer. Cancer Res 77:3922–3930PubMedCrossRef
67.
Song Z, Liu T, Shi L et al (2021) The deep learning model combining CT image and clinicopathological information for predicting ALK fusion status and response to ALK-TKI therapy in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging 48:361–371PubMedCrossRef
68.
Lu X, Li M, Zhang H et al (2020) A novel radiomic nomogram for predicting epidermal growth factor receptor mutation in peripheral lung adenocarcinoma. Phys Med Biol 65:055012PubMedCrossRef
69.
Lv J, Zhang H, Ma J et al (2018) Comparison of CT radiogenomic and clinical characteristics between EGFR and KRAS mutations in lung adenocarcinomas. Clin Radiol 73:590 e591–590 e598CrossRef
70.
Zhou M, Leung A, Echegaray S et al (2018) Non-small cell lung cancer radiogenomics map identifies relationships between molecular and imaging phenotypes with prognostic implications. Radiology 286:307–315PubMedCrossRef
71.
Sacconi B, Anzidei M, Leonardi A et al (2017) Analysis of CT features and quantitative texture analysis in patients with lung adenocarcinoma: a correlation with EGFR mutations and survival rates. Clin Radiol 72:443–450PubMedCrossRef
72.
Kim TJ, Lee CT, Jheon SH, Park JS, Chung JH (2016) Radiologic characteristics of surgically resected non-small cell lung cancer with ALK rearrangement or EGFR mutations. Ann Thorac Surg 101:473–480PubMedCrossRef
73.
Blackhall FH, Peters S, Bubendorf L et al (2014) Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J Clin Oncol 32:2780–2787PubMedCrossRef
74.
Solomon BJ, Kim DW, Wu YL et al (2018) Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer. J Clin Oncol 36:2251–2258PubMedCrossRef
75.
Ou SH, Ahn JS, De Petris L et al (2016) Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 34:661–668PubMedCrossRef
76.
Yamamoto S, Maki DD, Korn RL, Kuo MD (2012) Radiogenomic analysis of breast cancer using MRI: a preliminary study to define the landscape. AJR Am J Roentgenol 199:654–663PubMedCrossRef
77.
Gierach GL, Li H, Loud JT et al (2014) Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study. Breast Cancer Res 16:424PubMedPubMedCentral
78.
Tamez-Pena JG, Rodriguez-Rojas JA, Gomez-Rueda H et al (2018) Radiogenomics analysis identifies correlations of digital mammography with clinical molecular signatures in breast cancer. PLoS One 13:e0193871PubMedPubMedCentralCrossRef
79.
Zhou J, Tan H, Bai Y et al (2019) Evaluating the HER-2 status of breast cancer using mammography radiomics features. Eur J Radiol 121:108718PubMedCrossRef
80.
81.
Grimm LJ, Zhang J, Mazurowski MA (2015) Computational approach to radiogenomics of breast cancer: luminal A and luminal B molecular subtypes are associated with imaging features on routine breast MRI extracted using computer vision algorithms. J Magn Reson Imaging 42:902–907PubMedCrossRef
82.
Park EK, Lee KS, Seo BK et al (2019) Machine learning approaches to radiogenomics of breast cancer using low-dose perfusion computed tomography: predicting prognostic biomarkers and molecular subtypes. Sci Rep 9:17847PubMedPubMedCentralCrossRef
83.
Saha A, Harowicz MR, Grimm LJ et al (2018) A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features. Br J Cancer 119:508–516PubMedPubMedCentralCrossRef
84.
Li H, Zhu Y, Burnside ES et al (2016) Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set. NPJ Breast Cancer 2:16012PubMedPubMedCentralCrossRef
85.
Mazurowski MA, Zhang J, Grimm LJ, Yoon SC, Silber JI (2014) Radiogenomic analysis of breast cancer: luminal B molecular subtype is associated with enhancement dynamics at MR imaging. Radiology 273:365–372PubMedCrossRef
86.
Holli-Helenius K, Salminen A, Rinta-Kiikka I et al (2017) MRI texture analysis in differentiating luminal A and luminal B breast cancer molecular subtypes - a feasibility study. BMC Med Imaging 17:69PubMedPubMedCentralCrossRef
87.
Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER (2008) Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 8:155PubMedPubMedCentralCrossRef
88.
Riedl CC, Luft N, Bernhart C et al (2015) Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol 33:1128–1135PubMedPubMedCentralCrossRef
89.
Pinker K, Chin J, Melsaether AN, Morris EA, Moy L (2018) Precision medicine and radiogenomics in breast cancer: new approaches toward diagnosis and treatment. Radiology 287:732–747PubMedCrossRef
90.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672PubMedCrossRef
91.
Cameron D, Piccart-Gebhart MJ, Gelber RD et al (2017) 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389:1195–1205PubMedPubMedCentralCrossRef
92.
93.
Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70CrossRef
94.
Guiu S, Michiels S, Andre F et al (2012) Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol 23:2997–3006PubMedCrossRef
95.
96.
Guo F, Gong H, Zhao H et al (2018) Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients. Sci Rep 8:6076PubMedPubMedCentralCrossRef
97.
98.
Seppala TT, Bohm JP, Friman M et al (2015) Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br J Cancer 112:1966–1975PubMedPubMedCentralCrossRef
99.
Modest DP, Ricard I, Heinemann V et al (2016) Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol 27:1746–1753PubMedPubMedCentralCrossRef
100.
Schirripa M, Cremolini C, Loupakis F et al (2015) Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int J Cancer 136:83–90PubMedCrossRef
101.
Margonis GA, Buettner S, Andreatos N et al (2018) Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer. JAMA Surg 153:e180996PubMedPubMedCentralCrossRef
102.
Okuno M, Goumard C, Kopetz S et al (2018) RAS Mutation is associated with unsalvageable recurrence following hepatectomy for colorectal cancer liver metastases. Ann Surg Oncol 25:2457–2466PubMedCrossRef
103.
Strickler JH, Wu C, Bekaii-Saab T (2017) Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. Cancer Treat Rev 60:109–119PubMedCrossRef
104.
Sundar R, Hong DS, Kopetz S, Yap TA (2017) Targeting BRAF-mutant colorectal cancer: progress in combination strategies. Cancer Discov 7:558–560PubMedPubMedCentralCrossRef
105.
Peeters M, Oliner KS, Price TJ et al (2015) Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin Cancer Res 21:5469–5479PubMedCrossRef
106.
Barras D, Missiaglia E, Wirapati P et al (2017) BRAF V600E mutant colorectal cancer subtypes based on gene expression. Clin Cancer Res 23:104–115PubMedCrossRef
107.
Yang L, Dong D, Fang M et al (2018) Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer? Eur Radiol 28:2058–2067PubMedCrossRef
108.
Lubner MG, Stabo N, Lubner SJ et al (2015) CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes. Abdom Imaging 40:2331–2337PubMedCrossRef
109.
Taguchi N, Oda S, Yokota Y et al (2019) CT texture analysis for the prediction of KRAS mutation status in colorectal cancer via a machine learning approach. Eur J Radiol 118:38–43PubMedCrossRef
110.
Negreros-Osuna AA, Parakh A, Corcoran RB et al (2020) Radiomics texture features in advanced colorectal cancer: correlation with BRAF mutation and 5-year overall survival. Radiol Imaging Cancer 2:e190084PubMedPubMedCentralCrossRef
111.
112.
Cui Y, Liu H, Ren J et al (2020) Development and validation of a MRI-based radiomics signature for prediction of KRAS mutation in rectal cancer. Eur Radiol 30:1948–1958PubMedCrossRef
113.
Oh JE, Kim MJ, Lee J et al (2020) Magnetic resonance-based texture analysis differentiating KRAS mutation status in rectal cancer. Cancer Res Treat 52:51–59PubMedCrossRef
114.
Lovinfosse P, Koopmansch B, Lambert F et al (2016) (18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status. Br J Radiol 89:20160212PubMedPubMedCentralCrossRef
115.
Chen SW, Chiang HC, Chen WT et al (2014) Correlation between PET/CT parameters and KRAS expression in colorectal cancer. Clin Nucl Med 39:685–689PubMedCrossRef
116.
Cho A, Jo K, Hwang SH et al (2017) Correlation between KRAS mutation and (18)F-FDG uptake in stage IV colorectal cancer. Abdom Radiol (NY) 42:1621–1626CrossRef
117.
Lv Y, Wang X, Liang L, Wang L, Lu J (2019) SUVmax and metabolic tumor volume: surrogate image biomarkers of KRAS mutation status in colorectal cancer. Onco Targets Ther 12:2115–2121PubMedPubMedCentralCrossRef
118.
Hong HS, Kim SH, Park HJ et al (2013) Correlations of dynamic contrast-enhanced magnetic resonance imaging with morphologic, angiogenic, and molecular prognostic factors in rectal cancer. Yonsei Med J 54:123–130PubMedCrossRef
119.
Horvat N, Veeraraghavan H, Pelossof RA et al (2019) Radiogenomics of rectal adenocarcinoma in the era of precision medicine: a pilot study of associations between qualitative and quantitative MRI imaging features and genetic mutations. Eur J Radiol 113:174–181PubMedPubMedCentralCrossRef
120.
Krikelis D, Skoura E, Kotoula V et al (2014) Lack of association between KRAS mutations and 18F-FDG PET/CT in Caucasian metastatic colorectal cancer patients. Anticancer Res 34:2571–2579PubMed
121.
Oner AO, Budak ES, Yildirim S, Aydin F, Sezer C (2017) The value of (18)FDG PET/CT parameters, hematological parameters and tumor markers in predicting KRAS oncogene mutation in colorectal cancer. Hell J Nucl Med 20:160–165PubMed
122.
Kawada K, Toda K, Nakamoto Y et al (2015) Relationship Between 18F-FDG PET/CT Scans and KRAS Mutations in Metastatic Colorectal Cancer. J Nucl Med 56:1322–1327PubMedCrossRef
123.
Kim BJ, Kim JH, Kim HS, Zang DY (2017) Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review. Oncotarget 8:13979–13985PubMedPubMedCentralCrossRef
124.
Kim HS, Kim JH, Jang HJ, Han B, Zang DY (2018) Clinicopathologic significance of VHL gene alteration in clear-cell renal cell carcinoma: an updated meta-analysis and review. Int J Mol Sci 19:2529PubMedCentralCrossRef
125.
126.
Sato Y, Yoshizato T, Shiraishi Y et al (2013) Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 45:860–867PubMedCrossRef
127.
Wang Z, Peng S, Guo L et al (2018) Prognostic and clinicopathological value of PBRM1 expression in renal cell carcinoma. Clin Chim Acta 486:9–17PubMedCrossRef
128.
Hakimi AA, Ostrovnaya I, Reva B et al (2013) Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res 19:3259–3267PubMedPubMedCentralCrossRef
129.
Chen X, Zhou Z, Hannan R et al (2018) Reliable gene mutation prediction in clear cell renal cell carcinoma through multi-classifier multi-objective radiogenomics model. Phys Med Biol 63:215008PubMedPubMedCentralCrossRef
130.
Kocak B, Durmaz ES, Kaya OK, Kilickesmez O (2020) Machine learning-based unenhanced CT texture analysis for predicting BAP1 mutation status of clear cell renal cell carcinomas. Acta Radiol 61:856–864PubMedCrossRef
131.
Kocak B, Durmaz ES, Ates E, Ulusan MB (2019) Radiogenomics in clear cell renal cell carcinoma: machine learning-based high-dimensional quantitative CT texture analysis in predicting PBRM1 mutation status. AJR Am J Roentgenol 212:W55–W63PubMedCrossRef
132.
Li ZC, Zhai G, Zhang J et al (2019) Differentiation of clear cell and non-clear cell renal cell carcinomas by all-relevant radiomics features from multiphase CT: a VHL mutation perspective. Eur Radiol 29:3996–4007PubMedCrossRef
133.
Ghosh P, Tamboli P, Vikram R, Rao A (2015) Imaging-genomic pipeline for identifying gene mutations using three-dimensional intra-tumor heterogeneity features. J Med Imaging (Bellingham) 2:041009CrossRef
134.
Feng Z, Zhang L, Qi Z, Shen Q, Hu Z, Chen F (2020) Identifying BAP1 mutations in clear-cell renal cell carcinoma by CT radiomics: preliminary findings. Front Oncol 10:279PubMedPubMedCentralCrossRef
135.
Zeng H, Chen L, Wang M, Luo Y, Huang Y, Ma X (2021) Integrative radiogenomics analysis for predicting molecular features and survival in clear cell renal cell carcinoma. Aging (Albany NY) 13:9960–9975CrossRef
136.
137.
138.
Berenguer R, Pastor-Juan MDR, Canales-Vazquez J et al (2018) Radiomics of CT features may be nonreproducible and redundant: influence of CT acquisition parameters. Radiology 288:407–415PubMedCrossRef
139.
van Velden FH, Kramer GM, Frings V et al (2016) Repeatability of radiomic features in non-small-cell lung cancer [(18)F]FDG-PET/CT studies: impact of reconstruction and delineation. Mol Imaging Biol 18:788–795PubMedPubMedCentralCrossRef
140.
Pfaehler E, Beukinga RJ, de Jong JR et al (2019) Repeatability of (18) F-FDG PET radiomic features: a phantom study to explore sensitivity to image reconstruction settings, noise, and delineation method. Med Phys 46:665–678PubMedCrossRef
141.
Lecler A, Duron L, Balvay D et al (2019) Combining multiple magnetic resonance imaging sequences provides independent reproducible radiomics features. Sci Rep 9:2068PubMedPubMedCentralCrossRef
142.
He L, Huang Y, Ma Z, Liang C, Liang C, Liu Z (2016) Effects of contrast-enhancement, reconstruction slice thickness and convolution kernel on the diagnostic performance of radiomics signature in solitary pulmonary nodule. Sci Rep 6:34921PubMedPubMedCentralCrossRef
143.
Ligero M, Jordi-Ollero O, Bernatowicz K et al (2021) Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis. Eur Radiol 31:1460–1470PubMedCrossRef
Metadaten
Titel
The application of radiomics in predicting gene mutations in cancer
verfasst von
Yana Qi
Tingting Zhao
Mingyong Han
Publikationsdatum
20.01.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 6/2022
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-021-08520-6

Weitere Artikel der Ausgabe 6/2022

Radiological classification, gene-mutation status, and surgical prognosis of synchronous multiple primary lung cancer

  • Chest

Outcomes after primary and repeat thermal ablation of hepatocellular carcinoma with or without liver transplantation

  • Open Access
  • Interventional

Diagnostic validation of a deep learning nodule detection algorithm in low-dose chest CT: determination of optimized dose thresholds in a virtual screening scenario

  • Chest

MRI-derived radiomics analysis improves the noninvasive pretreatment identification of multimodality therapy candidates with early-stage cervical cancer

  • Imaging Informatics and Artificial Intelligence

The central vein sign helps in differentiating multiple sclerosis from its mimickers: lessons from Fabry disease

  • Magnetic Resonance

Breast cancer screening in women with extremely dense breasts recommendations of the European Society of Breast Imaging (EUSOBI)

  • Open Access
  • Breast

Neu im Fachgebiet Radiologie

Hölzerner Fremdkörper in der Orbita? Zuerst eine CT!

Besteht der Verdacht, dass ein Fremdkörper aus Holz in den Orbitalraum eingedrungen ist, spielt die Bildgebung eine entscheidende diagnostische Rolle. Was von CT und MRT zu erwarten ist, hat ein chinesisches Radiologenteam untersucht.

Diagnostik von Rippenfrakturen: KI schlägt Radiologen

Mensch gegen Maschine: Beim Erkennen von Rippenfrakturen in Röntgen- und CT-Aufnahmen entschied sich dieses Duell zugunsten der künstlichen Intelligenz (KI). Die Algorithmen zeigten eine höhere Sensitivität als ihre menschlichen Kollegen.

Ärztinnen überholen Ärzte bei Praxisgründungen

Bei Praxisgründungen haben inzwischen die Frauen deutlich die Nase vorn: Seit zehn Jahren wagen laut apoBank mehr Ärztinnen als Ärzte den Schritt in die Selbstständigkeit. In puncto Finanzierung sind sie aber vorsichtiger als die männlichen Kollegen.

Ambulante Behandlung darf länger dauern als stationäre

Ambulante Behandlungen haben Vorrang vor stationären - auch wenn diese läner dauern. Das hat das Bundessozialgericht klargestellt. Konkret ging es um Liposuktionen der Ober- und Unterschenkel.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise